The 2008 ASH Annual Meeting featured several important abstracts highlighting advances in the treatment of chronic lymphocytic leukemia (CLL).
Abstract 2091 updated results of a phase III study randomizing 319 previously untreated patients to chlorambucil or bendamustine [10] . OR, CR and median PFS favored bendamustine (67%, 32%, 21.5 months) over chlorambucil (30%, 2%, 8.3 months), although bendamustine caused greater hematologic toxicity (40% vs. 19%), especially grade 3-4 neutropenia (23% vs. 9%).
Two studies of lenalidomide in previously untreated patients were presented [11, 12] . Abstract 44 summarized results of a phase I study in 25 Canadian patients [11] . Due to grade 5 sepsis and grade 3-4 tumor lysis, the dose was decreased from 25 mg to 2.5 mg and then escalated to 10 mg daily for 21 days every 28 days. Toxicity included fatigue (78%), tumor flare (78%), rash (48%) and grade 3-4 neutropenia (43%). OR and CR were 65% and 0%, respectively. Abstract 45 presented a study in 43 elderly patients age 65 or older [12] . Lenalidomide was given continuously, and 5-10 mg daily was the median delivered dose. Grade 3-4 myelosuppression and tumor flare were observed in 26% and 44% of patients, respectively. OR and CR were 54% and 0%, respectively. While lenalidomide is clearly active in CLL, the absence of CR in previously untreated patients was disappointing.
Abstract 47 presented a phase II study giving high dose methylprednisolone 1000 mg/m 2 day 1-3 every four weeks and weekly rituximab (total dose 4500-6750 mg/ m 2 ) to 28 patients [13] . OR and CR were 96% and 32%, respectively. Patients were lesser splenomegaly and lower beta-2-microglobulin levels were more likely to respond.
In the relapsed setting, abstract 329 presented final results of the GCLLSG CLL2H study which administered subcutaneous alemtuzumab to 103 relapsed patients, many of whom had high-risk features [14] . Infusion toxicity was minimal, but grade 3-4 anemia (56%), thrombocytopenia (57%), anemia (49%), cytomegalovirus reactivation (8%) and non-CMV infection (29%) were significant toxicities. Seventy-five patients died; 56% died of progressive CLL, and 31% died of infection. OR (34%), CR (4%) and median PFS (7.7 months) were similar to the results achieved by intravenous alemtuzumab in the pivotal CAM211 study [15] .
Abstract 330 summarized a phase II GCLLSG trial administering bendamustine 70 mg/m2 on day 1-2 and rituximab 500 mg/m2 on day 1 to 81 relapsed CLL patients [16] . OR and CR were 77% and 15%, respectively. Twelve of 13 patients (92%) with del (11q22), 4/9 patients (44%) with del (17p13), and 29/39 patients (74%) responded, indicating that bendamustine is active in highrisk relapsed CLL.
Abstract 46 presented combined phase I/II results of flavopiridol (alvocidib) in 116 relapsed patients, 70% of whom were fludarabine-refractory [17] . OR in this highrisk population was 47%. Furthermore, 19/39 del (17p13) patients (49%), 28/47 del (11q22) patients (60%) and 22/52 complex karyotype patients (42%) responded, demonstrating the activity of flavopiridol in poor-risk groups with limited therapeutic options. Fortyone of 85 patients (48%) with bulky lymphadenopathy > 5 cm responded. Median PFS in responders was 10-12 months across all risk groups. A registration study is ongoing.
Finally, abstract 328 presented a pivotal phase II study of the fully humanized anti-CD20 antibody ofatumumab (HuMax-CD20) in relapsed patients refractory to both fludarabine and alemtuzumab (DR, n = 59) or with bulky lymphadenopathy refractory to fludarabine (BFR, n = 79) [18] . OR, time to next therapy, and OS were similar for the DR (51%, 9.0 months, 13.7 months) and BFR groups (44%, 7.9 months, 15.4 months). These results have been submitted for FDA approval.
